temozolomide has been researched along with Germinoblastoma in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal was to determine whether the addition of temozolomide (TMZ) to the standard treatment of high-dose methotrexate (HD-MTX) and whole-brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL) improves survival." | 9.69 | Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. ( Abe, K; Arakawa, Y; Asai, A; Asano, K; Fukuda, H; Gomyo, M; Katayama, H; Kinoshita, M; Koga, T; Kojima, M; Mishima, K; Mizusawa, J; Momii, Y; Nagane, M; Nakamura, S; Narita, Y; Natsumeda, M; Nishikawa, R; Sasaki, A; Sasaki, H; Sasaki, N; Sasayama, T; Shibahara, I; Shinojima, N; Sumi, M; Tamaru, JI; Tsuchiya, K; Tsurubuchi, T; Yamasaki, F; Yoshimoto, K, 2023) |
| "This study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and subsequent TMZ." | 9.22 | Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. ( Augspurger, M; Bartlett, NL; Bokstein, F; Bovi, JA; Brat, D; Fisher, BJ; Glass, J; Liepman, MK; Mehta, MP; Schultz, CJ; Solhjem, MC; Suh, JH; Werner-Wasik, M; Won, M, 2016) |
| "Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL)." | 9.17 | O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. ( Austin, AD; Desjardins, A; Friedman, HS; Herndon, JE; Jiang, X; McLendon, RE; Quinn, JA; Reardon, DA; Vredenburgh, JJ, 2013) |
| "We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies." | 9.17 | Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. ( Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY, 2013) |
| "To compare results of treatment with temozolomide or dacarbazine, in combination with an anthracycline, in dogs with relapsed or refractory lymphoma." | 9.12 | Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. ( Cadile, CD; Dervisis, NG; Dominguez, PA; Kitchell, BE; Newman, RG; Sarbu, L; Swanson, CN, 2007) |
| "Enhanced drug localization at the tumor sites with minimal toxicity was demonstrated using dendrimer-conjugated temozolomide for treating experimental lymphoma, developed as a solid tumor." | 8.02 | Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy. ( Hira, SK; Manna, PP; Rej, A; RoyMahapatra, D; Sk, UH, 2021) |
| "Temozolomide (TMZ) is an alkylating agent previously used in conjunction with doxorubicin (DOX) to treat dogs with relapsed lymphoma." | 7.88 | Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma. ( Baines, SJ; Blackwood, L; Elliott, JW; Treggiari, E, 2018) |
| "This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities." | 7.76 | Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. ( Glas, M; Herrlinger, U; Kurzwelly, D; Lohner, H; Reifenberger, G; Roth, P; Schabet, M; Waha, A; Weimann, E; Weller, M, 2010) |
| "Temozolomide (TMZ), a DNA alkylating agent used in the treatment of melanoma, is believed to mediate its effect by addition of a methyl group to the O(6) position of guanine in DNA." | 7.74 | Temozolomide induces senescence but not apoptosis in human melanoma cells. ( Allen, J; Avery-Kiejda, KA; Hersey, P; Mhaidat, NM; Scott, RJ; Zhang, XD, 2007) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 7.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| "Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non-Hodgkin lymphoma developed recurrent lymphoma in the brain only." | 7.72 | Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. ( Barron, L; Tishler, R; Wong, ET; Wu, JK, 2004) |
| "Temozolomide has emerged as a new alternative treatment for PCNSL and constitutes an attractive option for the elderly because of its favorable toxicity profile." | 6.73 | Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. ( Barrie, M; Carnin, C; Chinot, O; Hoang-Xuan, K; Omuro, AM; Taillandier, L, 2007) |
| "Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT)." | 6.71 | Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. ( Abbadessa, A; Bernardi, D; Bordonaro, R; Candela, M; Dell'Oro, S; Ferreri, AJ; Franceschi, E; Latte, G; Mason, W; Pace, A; Perry, J; Reni, M; Stelitano, C; Villa, E; Zaja, F, 2004) |
| "The goal was to determine whether the addition of temozolomide (TMZ) to the standard treatment of high-dose methotrexate (HD-MTX) and whole-brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL) improves survival." | 5.69 | Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. ( Abe, K; Arakawa, Y; Asai, A; Asano, K; Fukuda, H; Gomyo, M; Katayama, H; Kinoshita, M; Koga, T; Kojima, M; Mishima, K; Mizusawa, J; Momii, Y; Nagane, M; Nakamura, S; Narita, Y; Natsumeda, M; Nishikawa, R; Sasaki, A; Sasaki, H; Sasaki, N; Sasayama, T; Shibahara, I; Shinojima, N; Sumi, M; Tamaru, JI; Tsuchiya, K; Tsurubuchi, T; Yamasaki, F; Yoshimoto, K, 2023) |
| "This study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and subsequent TMZ." | 5.22 | Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. ( Augspurger, M; Bartlett, NL; Bokstein, F; Bovi, JA; Brat, D; Fisher, BJ; Glass, J; Liepman, MK; Mehta, MP; Schultz, CJ; Solhjem, MC; Suh, JH; Werner-Wasik, M; Won, M, 2016) |
| "Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL)." | 5.17 | O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. ( Austin, AD; Desjardins, A; Friedman, HS; Herndon, JE; Jiang, X; McLendon, RE; Quinn, JA; Reardon, DA; Vredenburgh, JJ, 2013) |
| "We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies." | 5.17 | Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. ( Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY, 2013) |
| "We evaluated a novel therapy for primary central nervous system lymphoma (PCNSL) with induction immunochemotherapy with high-dose methotrexate, temozolomide, and rituximab (MT-R) followed by intensive consolidation with infusional etoposide and high-dose cytarabine (EA)." | 5.16 | Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. ( Behler, CM; Cha, S; Damon, LE; Hwang, J; Issa, S; McDermott, M; O'Brien, J; Rubenstein, JL; Shuman, MA; Treseler, P; Valles, F; Wieduwilt, MJ, 2012) |
| "To compare results of treatment with temozolomide or dacarbazine, in combination with an anthracycline, in dogs with relapsed or refractory lymphoma." | 5.12 | Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. ( Cadile, CD; Dervisis, NG; Dominguez, PA; Kitchell, BE; Newman, RG; Sarbu, L; Swanson, CN, 2007) |
| "Enhanced drug localization at the tumor sites with minimal toxicity was demonstrated using dendrimer-conjugated temozolomide for treating experimental lymphoma, developed as a solid tumor." | 4.02 | Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy. ( Hira, SK; Manna, PP; Rej, A; RoyMahapatra, D; Sk, UH, 2021) |
| "Temozolomide (TMZ) is an alkylating agent previously used in conjunction with doxorubicin (DOX) to treat dogs with relapsed lymphoma." | 3.88 | Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma. ( Baines, SJ; Blackwood, L; Elliott, JW; Treggiari, E, 2018) |
| "This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities." | 3.76 | Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. ( Glas, M; Herrlinger, U; Kurzwelly, D; Lohner, H; Reifenberger, G; Roth, P; Schabet, M; Waha, A; Weimann, E; Weller, M, 2010) |
| "Temozolomide (TMZ), a DNA alkylating agent used in the treatment of melanoma, is believed to mediate its effect by addition of a methyl group to the O(6) position of guanine in DNA." | 3.74 | Temozolomide induces senescence but not apoptosis in human melanoma cells. ( Allen, J; Avery-Kiejda, KA; Hersey, P; Mhaidat, NM; Scott, RJ; Zhang, XD, 2007) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 3.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| "Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non-Hodgkin lymphoma developed recurrent lymphoma in the brain only." | 3.72 | Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. ( Barron, L; Tishler, R; Wong, ET; Wu, JK, 2004) |
| "Malignant primary brain tumors cause more than 15 000 deaths per year in the United States." | 3.01 | Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. ( Mellinghoff, IK; Schaff, LR, 2023) |
| "Temozolomide has emerged as a new alternative treatment for PCNSL and constitutes an attractive option for the elderly because of its favorable toxicity profile." | 2.73 | Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. ( Barrie, M; Carnin, C; Chinot, O; Hoang-Xuan, K; Omuro, AM; Taillandier, L, 2007) |
| "Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT)." | 2.71 | Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. ( Abbadessa, A; Bernardi, D; Bordonaro, R; Candela, M; Dell'Oro, S; Ferreri, AJ; Franceschi, E; Latte, G; Mason, W; Pace, A; Perry, J; Reni, M; Stelitano, C; Villa, E; Zaja, F, 2004) |
| "Temozolomide has recently emerged as an alternative option for PCNSL treatment." | 1.40 | MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. ( Canal, F; Cavallin, S; Dei Tos, AP; Gherlinzoni, F; Scarpa, M; Scquizzato, E; Stefani, PM; Toffolatti, L, 2014) |
| "Temozolomide has become the standard of care in newly diagnosed glioblastoma." | 1.35 | [Chemotherapy for brain tumors in adult patients]. ( Weller, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.33) | 18.7374 |
| 1990's | 2 (4.65) | 18.2507 |
| 2000's | 17 (39.53) | 29.6817 |
| 2010's | 17 (39.53) | 24.3611 |
| 2020's | 6 (13.95) | 2.80 |
| Authors | Studies |
|---|---|
| Sk, UH | 1 |
| Hira, SK | 1 |
| Rej, A | 1 |
| RoyMahapatra, D | 1 |
| Manna, PP | 1 |
| Mishima, K | 1 |
| Nishikawa, R | 1 |
| Narita, Y | 1 |
| Mizusawa, J | 1 |
| Sumi, M | 1 |
| Koga, T | 1 |
| Sasaki, N | 1 |
| Kinoshita, M | 1 |
| Nagane, M | 1 |
| Arakawa, Y | 1 |
| Yoshimoto, K | 1 |
| Shibahara, I | 1 |
| Shinojima, N | 1 |
| Asano, K | 1 |
| Tsurubuchi, T | 1 |
| Sasaki, H | 1 |
| Asai, A | 1 |
| Sasayama, T | 1 |
| Momii, Y | 1 |
| Sasaki, A | 1 |
| Nakamura, S | 1 |
| Kojima, M | 1 |
| Tamaru, JI | 1 |
| Tsuchiya, K | 1 |
| Gomyo, M | 1 |
| Abe, K | 1 |
| Natsumeda, M | 1 |
| Yamasaki, F | 1 |
| Katayama, H | 1 |
| Fukuda, H | 1 |
| Bromberg, JEC | 1 |
| Doorduijn, JK | 1 |
| Schaff, LR | 1 |
| Mellinghoff, IK | 1 |
| David, KA | 1 |
| Sundaram, S | 1 |
| Kim, SH | 1 |
| Vaca, R | 1 |
| Lin, Y | 1 |
| Singer, S | 1 |
| Malecek, MK | 1 |
| Carter, J | 1 |
| Zayac, A | 1 |
| Kim, MS | 1 |
| Reddy, N | 1 |
| Ney, D | 1 |
| Habib, A | 1 |
| Strouse, C | 1 |
| Graber, J | 1 |
| Bachanova, V | 1 |
| Salman, S | 1 |
| Vendiola, JA | 1 |
| Hossain, N | 1 |
| Tsang, M | 1 |
| Major, A | 1 |
| Bond, DA | 1 |
| Agrawal, P | 1 |
| Mier-Hicks, A | 1 |
| Torka, P | 1 |
| Rajakumar, P | 1 |
| Venugopal, P | 1 |
| Berg, S | 1 |
| Glantz, M | 1 |
| Goldlust, SA | 1 |
| Folstad, M | 1 |
| Kumar, P | 1 |
| Ollila, TA | 1 |
| Cai, J | 1 |
| Spurgeon, S | 1 |
| Sieg, A | 1 |
| Cleveland, J | 1 |
| Chang, J | 1 |
| Epperla, N | 1 |
| Karmali, R | 1 |
| Naik, S | 1 |
| Martin, P | 1 |
| Smith, SM | 1 |
| Rubenstein, J | 1 |
| Kahl, B | 1 |
| Evens, AM | 1 |
| Baron, M | 1 |
| Belin, L | 1 |
| Cassoux, N | 2 |
| Fardeau, C | 1 |
| Blaizeau, M | 1 |
| Soussain, C | 3 |
| Houillier, C | 3 |
| Hoang-Xuan, K | 4 |
| Gyan, E | 2 |
| Le Lez, ML | 1 |
| Lavaud, A | 1 |
| Soubeyran, P | 2 |
| Bodaghi, B | 2 |
| Costopoulos, M | 2 |
| Leblond, V | 1 |
| Touitou, V | 3 |
| Maloum, K | 1 |
| Errera, MH | 1 |
| Roos-Weil, D | 1 |
| Le Garff-Tavernier, M | 1 |
| Choquet, S | 3 |
| DeFilipp, Z | 1 |
| Li, S | 1 |
| El-Jawahri, A | 1 |
| Armand, P | 1 |
| Nayak, L | 2 |
| Wang, N | 1 |
| Batchelor, TT | 2 |
| Chen, YB | 1 |
| Abbassi, M | 1 |
| Riley, R | 1 |
| Malkin, M | 1 |
| Tang, Y | 1 |
| Rajendran, B | 1 |
| Yazbeck, V | 1 |
| Treggiari, E | 1 |
| Elliott, JW | 1 |
| Baines, SJ | 1 |
| Blackwood, L | 1 |
| Clark, SW | 1 |
| Taylor, J | 1 |
| Wang, DL | 1 |
| Abramson, JS | 1 |
| Jiang, X | 1 |
| Reardon, DA | 2 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Quinn, JA | 1 |
| Austin, AD | 1 |
| Herndon, JE | 1 |
| McLendon, RE | 1 |
| Friedman, HS | 1 |
| Wang, XX | 1 |
| Huang, HQ | 1 |
| Bai, B | 1 |
| Cai, QQ | 1 |
| Cai, QC | 1 |
| Gao, Y | 1 |
| Xia, YF | 1 |
| Xia, ZJ | 1 |
| Jiang, WQ | 1 |
| Toffolatti, L | 1 |
| Scquizzato, E | 1 |
| Cavallin, S | 1 |
| Canal, F | 1 |
| Scarpa, M | 1 |
| Stefani, PM | 1 |
| Gherlinzoni, F | 1 |
| Dei Tos, AP | 1 |
| Omuro, A | 3 |
| Chinot, O | 2 |
| Taillandier, L | 2 |
| Ghesquieres, H | 1 |
| Delwail, V | 1 |
| Lamy, T | 1 |
| Gressin, R | 1 |
| Huchet, A | 1 |
| Benouaich-Amiel, A | 2 |
| Lebouvier-Sadot, S | 1 |
| Barrié, M | 2 |
| del Rio, MS | 1 |
| Gonzalez-Aguilar, A | 1 |
| Delgadillo, D | 1 |
| Lacomblez, L | 1 |
| Tanguy, ML | 1 |
| Glass, J | 1 |
| Won, M | 1 |
| Schultz, CJ | 1 |
| Brat, D | 1 |
| Bartlett, NL | 1 |
| Suh, JH | 1 |
| Werner-Wasik, M | 1 |
| Fisher, BJ | 1 |
| Liepman, MK | 1 |
| Augspurger, M | 1 |
| Bokstein, F | 1 |
| Bovi, JA | 1 |
| Solhjem, MC | 1 |
| Mehta, MP | 1 |
| Nguyen, DT | 1 |
| Le Cossec, C | 1 |
| Legarf-Tavernier, M | 1 |
| LeHoang, P | 1 |
| Kadoch, C | 1 |
| Dinca, EB | 1 |
| Voicu, R | 1 |
| Chen, L | 1 |
| Nguyen, D | 1 |
| Parikh, S | 1 |
| Karrim, J | 1 |
| Shuman, MA | 2 |
| Lowell, CA | 1 |
| Treseler, PA | 1 |
| James, CD | 1 |
| Rubenstein, JL | 2 |
| Kurzwelly, D | 1 |
| Glas, M | 1 |
| Roth, P | 1 |
| Weimann, E | 1 |
| Lohner, H | 1 |
| Waha, A | 1 |
| Schabet, M | 1 |
| Reifenberger, G | 1 |
| Weller, M | 3 |
| Herrlinger, U | 2 |
| Yamanaka, R | 1 |
| Makino, K | 1 |
| Nakamura, H | 1 |
| Hide, T | 1 |
| Kuratsu, J | 1 |
| Murakami, M | 1 |
| Fujimaki, T | 1 |
| Asano, S | 1 |
| Nakaguchi, H | 1 |
| Yamada, SM | 1 |
| Hoya, K | 1 |
| Yamazaki, K | 1 |
| Ishida, Y | 1 |
| Matsuno, A | 1 |
| Wieduwilt, MJ | 1 |
| Valles, F | 1 |
| Issa, S | 1 |
| Behler, CM | 1 |
| Hwang, J | 1 |
| McDermott, M | 1 |
| Treseler, P | 1 |
| O'Brien, J | 1 |
| Cha, S | 1 |
| Damon, LE | 1 |
| Falchi, L | 1 |
| Gunnellini, M | 1 |
| Ferranti, L | 1 |
| Liberati, AM | 1 |
| Abrey, LE | 1 |
| Drappatz, J | 1 |
| Gilbert, MR | 1 |
| Wen, PY | 1 |
| Prados, M | 1 |
| Deangelis, LM | 1 |
| Wong, SF | 1 |
| Gan, HK | 1 |
| Cher, L | 1 |
| Tentori, L | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| D'Amati, G | 1 |
| Vergati, M | 1 |
| Portarena, I | 1 |
| Xu, W | 1 |
| Kalish, V | 1 |
| Zupi, G | 1 |
| Zhang, J | 1 |
| Graziani, G | 1 |
| Wong, ET | 2 |
| Tishler, R | 1 |
| Barron, L | 1 |
| Wu, JK | 1 |
| Reni, M | 2 |
| Mason, W | 2 |
| Zaja, F | 2 |
| Perry, J | 2 |
| Franceschi, E | 2 |
| Bernardi, D | 1 |
| Dell'Oro, S | 1 |
| Stelitano, C | 2 |
| Candela, M | 2 |
| Abbadessa, A | 2 |
| Pace, A | 2 |
| Bordonaro, R | 2 |
| Latte, G | 2 |
| Villa, E | 1 |
| Ferreri, AJ | 2 |
| Pitini, V | 2 |
| Arrigo, C | 2 |
| Righi, M | 1 |
| Delattre, JY | 2 |
| Baldari, S | 1 |
| Altavilla, G | 1 |
| Naro, C | 1 |
| Perniciaro, F | 1 |
| Sanson, M | 1 |
| Mazza, E | 1 |
| Spina, M | 1 |
| Ilariucci, F | 1 |
| Faedi, M | 1 |
| Corazzelli, G | 1 |
| Manno, P | 1 |
| Santisteban, M | 1 |
| Nieto, Y | 1 |
| De la Cruz, S | 1 |
| Aristu, J | 1 |
| Zubieta, JL | 1 |
| Fernández Hidalgo, O | 1 |
| Dervisis, NG | 1 |
| Dominguez, PA | 1 |
| Sarbu, L | 1 |
| Newman, RG | 1 |
| Cadile, CD | 1 |
| Swanson, CN | 1 |
| Kitchell, BE | 1 |
| Omuro, AM | 1 |
| Carnin, C | 1 |
| Mhaidat, NM | 1 |
| Zhang, XD | 1 |
| Allen, J | 1 |
| Avery-Kiejda, KA | 1 |
| Scott, RJ | 1 |
| Hersey, P | 1 |
| Küker, W | 1 |
| Platten, M | 1 |
| Dichgans, J | 1 |
| Tsang, LL | 2 |
| Quarterman, CP | 1 |
| Gescher, A | 2 |
| Slack, JA | 2 |
| Farmer, PB | 1 |
| Tisdale, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly[NCT00503594] | Phase 2 | 92 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma[NCT00068250] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)[NCT01735747] | Phase 2 | 16 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: A Pilot Study[NCT00416819] | 10 participants (Actual) | Interventional | 2003-09-30 | Completed | |||
| A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma[NCT00248534] | Phase 2 | 16 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to slow accrual/lack of resources/low priority due to combining 2 consortia) | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma[NCT03536039] | Phase 2 | 28 participants (Actual) | Interventional | 2016-01-27 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A dose limiting toxicity (DLT) is defined as any grade 3 or 4 non-hematological toxicity (other than grade 3 nausea/vomiting) or any hematological toxicity resulting in the discontinuation of temozolomide. Toxicity evaluation for this dose escalation includes all toxicities occurring prior to the start of radiation therapy. If the patient did not receive radiation therapy, then toxicity evaluation included all toxicities occurring through week 15. Any grade 5 toxicity would result in immediate suspension of accrual. (NCT00068250)
Timeframe: From start of treatment to 10 weeks if radiation therapy received, to 15 weeks if not.
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Temozolomide 100mg | 1 |
| Phase I: Temozolomide150 mg | 3 |
Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. (Please note that this outcome measure is considered the primary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. ) (NCT00068250)
Timeframe: Analysis occured after all patients have been on study for 2 years. Maximum follow-up at time of analysis was 8.5 years.
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Temozolomide 100mg Arms | 80.8 |
Progression is defined as greater than 25% increase in enhancing tumor or the appearance of new lesions in the brain, eye, or the appearance of a new positive cerebrospinal fluid (CSF) cytology. The patient may be neurologically stable or worse and on stable or increasing doses of corticosteroid. Progression-free survival time is defined as time from registration to the date of progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. (Please note that this outcome measure is considered a secondary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. ) (NCT00068250)
Timeframe: Analysis occured after all patients have been on study for 2 years. Maximum follow-up at time of analysis was 8.5 years.
| Intervention | years (Median) |
|---|---|
| Combined Temozolomide 100mg Arms | 5.4 |
Tumor response was centrally reviewed. Complete response: Disappearance of all enhancing tumor, the patient must be off steroid therapy and neurologically stable or improved; partial response: ≥ 50% decrease in enhancing tumor; progressive disease: ≥ 25% increase in a lesion, progressive or newly emergent meningeal or ocular disease. (Please note that this outcome measure is considered a secondary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. ) (NCT00068250)
Timeframe: From start of treatment to 10 weeks if RT received, to 15 weeks if not.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Not evaluable | |
| Combined Temozolomide 100mg Arms | 18 | 12 | 2 | 3 |
(NCT00248534)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| IV Rituximab | 71 |
"Scan at 6 months~Complete response: Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable or improving neurological exam minimum of 4 wks~Partial response: Greater than or equal 50% reduction in tumor size on MRI, on sable or decreasing glucocorticoids with stable or improving neurological exam for a minimum of 4 wks.~Progressive disease: Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.~Stable disease: Clinical status and MRI does not qualify for complete response, partial response or progression" (NCT00248534)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| IV Rituximab | 13 |
The intent was to measure Median Overall Survival at 3 years, however only one participant was analyzable at this time point. Therefore, the number of participants who survived is reported instead. (NCT00248534)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| IV Rituximab | 1 |
Objective response rate of the combination of Rituximab and TMZ (NCT00248534)
Timeframe: 2 months
| Intervention | percent of participants (Number) |
|---|---|
| IV Rituximab | 14 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
4 reviews available for temozolomide and Germinoblastoma
| Article | Year |
|---|---|
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Treatment of Primary Central Nervous System Posttransplant Lymphoproliferative Disorder in an Adult Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Central Nervous System Neoplasms; Diff | 2019 |
[Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2009 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
12 trials available for temozolomide and Germinoblastoma
| Article | Year |
|---|---|
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
Topics: Antineoplastic Agents, Alkylating; Brain; Central Nervous System Neoplasms; Disease-Free Survival; H | 2023 |
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; | 2013 |
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2015 |
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemo | 2016 |
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemo | 2016 |
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemo | 2016 |
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemo | 2016 |
Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Diseases; Dacarba | 2004 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dog Diseases; | 2007 |
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Drug Evaluation; | 1990 |
Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Drug Evaluation; | 1990 |
Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Drug Evaluation; | 1990 |
Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Drug Evaluation; | 1990 |
27 other studies available for temozolomide and Germinoblastoma
| Article | Year |
|---|---|
Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biocompatible Materials; Cell Line, Tumor; Ce | 2021 |
Is there a future for maintenance temozolomide chemotherapy in PCNSL?
Topics: Brain; Dacarbazine; Humans; Lymphoma; Methotrexate; Temozolomide | 2023 |
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2023 |
Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Drug-Related Side Effects and Adverse Reactions; Eye Neoplasms; Fema | 2020 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central | 2017 |
Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2018 |
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphom | 2013 |
Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2014 |
MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma.
Topics: Adult; Aged; Biomarkers, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Methylation; Fema | 2014 |
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
Topics: Animals; Brain Neoplasms; Cell Polarity; Dacarbazine; DNA Modification Methylases; DNA Repair Enzyme | 2009 |
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2010 |
Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2012 |
Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasm | 2011 |
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neopla | 2012 |
A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disea | 2012 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inh | 2003 |
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2004 |
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; A | 2004 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2007 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Brain; Centra | 2007 |
Temozolomide induces senescence but not apoptosis in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzothiazoles; Cell Division; Cellular Senescence; Da | 2007 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
First-line therapy with temozolomide induces regression of primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Huma | 2002 |
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dacarbazine; Ly | 1991 |
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dacarbazine; Ly | 1991 |
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dacarbazine; Ly | 1991 |
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dacarbazine; Ly | 1991 |
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Chlorambucil; Colonic Neoplasms; Dacarbaz | 1987 |